Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/23/2026

1. IBM
2. PRIM
3. META
4. KFY
5. ABBV
6. MU
7. DPZ
8. NAVN
9. DFTX
10. NVEC

Go back to Sarepta Therapeutics Announces Fourth Quarter 2018 and Full-Year 2018 Financial Results and Recent Corporate Developments

Sarepta Therapeutics (SRPT) PT Lowered to $192 at RBC Capital; Now a Full-Fledged Gene Therapy Company

February 28, 2019 6:51 AM EST

RBC Capital analyst Brian Abrahams lowered the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $192.00 (from $199.00) while maintaining a Outperform rating.

"We believe this quarter is marking the emergence of SRPT as a full-fledged gene therapy company and leader in neuro GT drug... More

Sarepta Therapeutics (SRPT) PT Raised to $213 at Cowen

February 28, 2019 6:21 AM EST

Cowen analyst Ritu Baral raised the price target on Sarepta Therapeutics (NASDAQ: SRPT) to $213.00 (from $178.00) while maintaining a Outperform rating.

Baral commented, "SRPT reported 4Q18 with pre-announced Exondys revenues only slightly below consensus but meeting FY18 guidance. SRPT provided timeline updates for its... More

Sarepta Therapeutics (SRPT) Tops Q4 EPS by 19c, Revenues Miss

February 27, 2019 4:15 PM EST

Sarepta Therapeutics (NASDAQ: SRPT) reported Q4 EPS of ($0.85), $0.19 better than the analyst estimate of ($1.04). Revenue for the quarter came in at $84.42 million versus the consensus estimate of $86.02 million.

2018 was a year of transformation for Sarepta. We continued to execute commercially, announced unprecedented early results... More